Takeda Can't Decertify Amitiza Class After $885M Jury Loss
A Massachusetts federal court refused Takeda's request to decertify a class of Amitiza buyers, after a jury awarded groups of purchasers a total of $885 million for claims that the drugmaker...To view the full article, register now.
Already a subscriber? Click here to view full article